The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEmmerson Regulatory News (EML)

Share Price Information for Emmerson (EML)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.90
Bid: 1.80
Ask: 2.00
Change: -0.10 (-5.00%)
Spread: 0.20 (11.111%)
Open: 2.00
High: 1.95
Low: 1.90
Prev. Close: 2.00
EML Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Raises £2.25 million in Oversubscribed Placement

12 Jul 2019 07:00

RNS Number : 3082F
Emmerson PLC
12 July 2019
 

Emmerson Plc / Ticker: EML / Index: LSE / Sector: Mining

12 July 2019

Raises £2.25 million in an Oversubscribed Placement to Fund the Continued Acceleration of Development of the World Class Khemisset Potash Project

 

Emmerson Plc ("Emmerson" or the "Company"), the Moroccan focused potash development company, is pleased to announce that it has raised £2.25 million (before expenses) through an oversubscribed placing of 60,000,000 new ordinary shares of no-par value each in the share capital of the Company ("Placing Shares") at a price of 3.75 pence per share (the "Issue Price") (collectively the "Fundraising").

The placing was led by joint brokers Shard Capital Partners LLC ("Shard") and Optiva Securities Limited ("Optiva"). The funds raised will primarily support the Company as it continues to rapidly develop the world class Khemisset Potash Project ("Khemisset" or the "Project") through the delivery of key work streams.

Hayden Locke, CEO of Emmerson, commented:

"The support that we have received in this fundraise, for which demand significantly exceeded our minimum targeted figure, is very encouraging and demonstrates a strong belief from our investors in the potential of Emmerson and the Khemisset Project.

"These funds enable us to continue our strategy of rapidly advancing the Project and our discussions with various potential strategic partners, without the pressure of impending short term capital requirements.

"The second half of the year will see significant project related news flow including metallurgical test work results, an updated Mineral Resource Estimate, various partner discussions in country, continuing offtake discussions and the delivery of the full Feasibility Study.

"This work builds upon the findings of the Scoping Study for Khemisset, which highlighted its sector leading capital costs and EBITDA margins, delivering post tax cash flow of nearly US$190 million per annum, and a post-tax NPV10 of US$1.14 billion using independent industry analyst price forecast.

The Emmerson team looks forward to continuing to update shareholders with details of our progress."

Details of the Fundraising

Use of proceeds

It is intended that the proceeds of the Fundraising will principally be used for the continuation of development of the Project post the delivery of the Feasibility Study, including progressing debt financing and strategic partner discussions, any additional technical work required post the Feasibility Study including further drilling, metallurgical testing and engineering studies and to cover general working capital expenses for the Company.

Admission and Total Voting Rights

The Company has raised £2.25 million, before expenses, through the issue of the Placing Shares with certain existing Shareholders and new investors.

Accordingly, an application has been made for the Placing Shares to be admitted to the Official List of the UK Listing Authority by way of a Standard Listing ("Admission") and it is expected that Admission will become effective and dealing in the Placing Shares will commence on or around the 16th of July 2019. The Placing Shares will rank pari passu with the existing ordinary shares of the Company. 

Following Admission, the enlarged issued share capital of the Company will comprise of 686,132,385 ordinary shares of no-par value each. No ordinary shares are held in Treasury. The total number of voting rights in the Company is therefore 686,132,385.

The above figure of 686,132,385 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

**ENDS**

For further information, please visit www.emmersonplc.com, follow us on Twitter (@emmerson_plc), or contact: 

Hayden Locke

Emmerson Plc

Tel: +44 (0) 207 236 1177

Edward McDermott

 

 

 

Jeremy King

 

Optiva Securities Limited

Joint Broker

Tel: +44 (0) 3137 1904

 

 

 

Damon Heath

Isabella Pierre

Shard Capital Partners LLC

Tel: +44 (0) 7186 9007

Gaby Jenner

Melissa Hancock

St Brides Partners Ltd

Financial PR/IR

Tel: +44 (0) 20 7236 1177

 

 

 

 

 

 

 

Notes to Editors

Emmerson's primary focus is on developing the Project located in Northern Morocco. The Project has a large JORC Resource Estimate (2012) of 311.4Mt @ 10.2% K2O and significant exploration potential with an accelerated development pathway targeting a low capex, high margin mine. Khemisset is perfectly located to capitalise on the expected growth of African fertiliser consumption whilst also being located on the doorstep of European markets. This unique positioning means the Project will receive a premium netback price compared to existing potash producers. The need to feed the world's rapidly increasing population is driving demand for potash and Emmerson is well placed to benefit from the opportunities this presents. The Scoping Study released in November 2018 indicated Khemisset has the potential to be among the lowest capital cost development stage potash projects in the world and also, as a result of its location, one of the highest margin projects. This delivered outstanding economics including a post-tax NPV10 of US$1.14 billion using industry expert, Argus', price forecasts.

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOERBMMTMBABTJL
Date   Source Headline
24th May 20247:00 amRNS2023 Financial Results
22nd Apr 202411:47 amRNSTR-1: Notification of major holdings
8th Apr 20244:45 pmRNSResults of Oversubscribed REX Retail Offer
8th Apr 20247:01 amRNSREX Retail Offer
8th Apr 20247:00 amRNSQ1 Update, Equity Placing and Retail Offer
11th Mar 20247:00 amRNSCommittee Upholds Environmental Approval Referral
1st Feb 20247:00 amRNSScoping Study on Breakthrough New Processing Route
8th Jan 20247:00 amRNSQ4 Update
21st Dec 20237:00 amRNSExtension of Mandated Lead Arrangers
26th Sep 20237:00 amRNSInterim Results for the six months to 30 June 2023
21st Sep 20237:00 amRNSQ3 2023 and Financing update
11th Sep 202311:38 amRNSMorocco Statement
11th Jul 202311:57 amRNSDirector/PDMR Shareholding
10th Jul 20234:30 pmRNSDirector/PDMR Shareholding
6th Jul 20232:49 pmRNSDirector/PDMR Shareholding
6th Jul 20237:00 amRNSQ2 Update
6th Jun 20237:00 amRNSExercise & Allotment of Shares
31st May 202312:01 pmRNSResult of AGM
5th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
13th Apr 20237:00 amRNS2022 Financial Results and Q1 Update
14th Feb 20237:00 amRNSMandated Lead Arrangers Appointed for Financing
9th Jan 20237:00 amRNSQ4 Update
3rd Jan 20237:00 amRNSAppointment of Liberum as Nominated Advisor
21st Nov 20227:00 amRNSPotash and Salt Offtake MOUs
27th Sep 20227:00 amRNSDirector/PDMR Shareholding
26th Sep 20221:45 pmRNSResults of REX Retail Offer & Total Voting Rights
26th Sep 20227:02 amRNSREX Retail Offer
26th Sep 20227:01 amRNSRenewal of Strategic Investment & Equity Placing
26th Sep 20227:00 amRNSInterim Results for the six months to 30 June 2022
16th Aug 20224:18 pmRNSExercise of Options & Director/PDMR Shareholding
22nd Jul 20229:00 amRNSShare Options Scheme & Director Shareholdings
19th Jul 20225:05 pmRNSReplacement: Director/PDMR Shareholding
18th Jul 20224:00 pmRNSDirector/PDMR Shareholding
11th Jul 20227:00 amRNSQ2 Activities Update
7th Jul 202212:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSExercise of Warrants and Issue of Shares
13th Jun 20227:00 amRNSNotice of AGM and Posting of Annual Report
31st May 20227:00 amRNSAudited Results for the year ended 31 Dec 2021
31st Mar 20227:00 amRNSQ1 Activities Update
15th Mar 20227:00 amRNSGrant of Share Options
21st Feb 20227:00 amRNSAppointment of Chief Financial Officer
16th Feb 20227:00 amRNSAppointment of Corporate Broker
27th Jan 20227:00 amRNSBasic Engineering Packages Awarded to Reminex S.A
25th Jan 20221:00 pmRNSPart Exercise of Options and Issue of Shares
31st Dec 20217:00 amRNSEnd of Year Newsletter
6th Dec 202112:45 pmRNSResult of AGM
6th Dec 202112:31 pmRNSResult of General Meeting
2nd Dec 20217:00 amRNSOperational Update: Khemisset Potash Project
29th Nov 20217:00 amRNSDirector/PDMR Shareholding
24th Nov 20217:00 amRNSIssue of Equity & Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.